DDR2 Antibody

What are the primary applications for DDR2 antibodies in research?

DDR2 antibodies are primarily employed in Western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry on paraffin-embedded tissues (IHC-P). For example, the DDR2 Antibody (3B11E4) is a mouse monoclonal IgG2a kappa antibody that can detect DDR2 protein from mouse, rat, and human origins across these applications . Research applications extend to studying DDR2's role in collagen signaling, matrix remodeling, and cell migration. When selecting an antibody, researchers should consider the specific application requirements, as some antibodies may perform better in certain techniques than others. For instance, in Simple Western applications, goat anti-human DDR2 antibodies have been successfully used at 2.5 μg/mL concentration to detect DDR2 at approximately 139 kDa .

How should DDR2 antibodies be validated before experimental use?

Proper validation of DDR2 antibodies should include multiple complementary approaches:

• Specificity testing using positive controls (e.g., HEK293 cells transfected with human DDR2)

• Negative controls (e.g., cells with DDR2 knockdown via siRNA)

• Cross-reactivity assessment (some antibodies show approximately 5% cross-reactivity with related proteins like DDR1)

• Confirmation of appropriate molecular weight detection (~130-139 kDa for full-length DDR2)

• Validation across multiple experimental methods

Particularly for immunoblotting applications, researchers should verify DDR2 antibody specificity by comparing detection in DDR2-expressing cells versus knockout/knockdown cells. For example, validation data from R&D Systems demonstrates the specificity of their anti-DDR2 antibody by showing detection in HEK293 cells transfected with human DDR2 but not in control cells .

What are the optimal storage and handling conditions for DDR2 antibodies?

For optimal performance and longevity of DDR2 antibodies:

• Store concentrated antibody solutions at -20°C for long-term storage

• For working solutions, store at 4°C for up to one month

• Avoid repeated freeze-thaw cycles (aliquot before freezing)

• When preparing dilutions, use appropriate buffers as recommended by the manufacturer

• For conjugated antibodies (FITC, PE, HRP), protect from light exposure to prevent photobleaching

Most commercial DDR2 antibodies are supplied at concentrations around 200 μg/ml and should maintain activity for at least 12 months when properly stored. Always centrifuge antibody vials briefly before opening to ensure collection of all liquid at the bottom of the vial .

What dilutions are recommended for common applications of DDR2 antibodies?

These ranges serve as starting points; optimization is essential for each experimental system. For example, R&D Systems' Human DDR2 Antibody (290804) has been validated at 15 μg/mL for immunohistochemistry on paraffin-embedded tissue sections with overnight incubation at 4°C .

How can DDR2 phosphorylation be effectively measured using antibody-based approaches?

Measuring DDR2 phosphorylation presents unique challenges due to the slow kinetics of DDR2 activation compared to other RTKs. Effective measurement requires:

• Time-course considerations: DDR2 phosphorylation occurs slowly, with peak activation often occurring 24 hours after collagen stimulation. Research data shows distinct temporal phosphorylation profiles for different DDR2 phosphorylation sites following collagen exposure .

• Phospho-specific antibodies: When available, these directly detect specific phosphorylated tyrosine residues (e.g., Tyr736 and Tyr740/741 in the activation loop).

• General phosphotyrosine antibodies: In the absence of site-specific antibodies, general anti-phosphotyrosine antibodies (like 4G10 or pY100) can be used following DDR2 immunoprecipitation .

• Quantitative analysis: Selected reaction monitoring (SRM) mass spectrometry has been successfully employed to quantify DDR2 phosphorylation at specific sites, showing significant increases in phosphorylation at Tyr736 and Tyr740/741 sites 24 hours post-collagen stimulation .

• Control experiments: Include kinase-dead DDR2 mutants (K608M and K608E) as negative controls to confirm that detected phosphorylation is dependent on DDR2 kinase activity .

For optimal results, researchers should allow sufficient time (24-48 hours) after collagen stimulation before assessing DDR2 phosphorylation, unlike other RTKs that activate within minutes.

What strategies can resolve common issues when detecting DDR2 in Western blotting?

When troubleshooting DDR2 detection by Western blotting, consider:

• Multiple bands/smearing: DDR2 undergoes extensive glycosylation and may appear as multiple bands (110-130 kDa range). To resolve this issue:

  • Include deglycosylation treatment (PNGase F) to obtain a single band

  • Use gradient gels (4-12%) for better separation of high molecular weight proteins

  • Extend blocking time to reduce non-specific binding

• Weak signal despite confirmed expression:

  • Increase protein loading (50-100 μg total protein)

  • Use enhanced chemiluminescence (ECL) detection systems

  • Consider using antibody conjugated to HRP directly to increase sensitivity

  • Extend primary antibody incubation to overnight at 4°C

• High background:

  • Increase washing steps (5-6 times, 10 minutes each)

  • Use optimized blocking agents (5% milk or BSA in TBST)

  • Reduce antibody concentration

  • Consider using m-IgGκ BP-HRP secondary antibody conjugates specifically designed for mouse monoclonal primary antibodies

• Phospho-DDR2 detection:

  • Include phosphatase inhibitors in all buffers

  • Pre-treat cells with phosphatase inhibitors (e.g., Calyculin A) to enhance phospho-signal

  • Use freshly prepared lysates (phosphorylation can be lost during storage)

How can DDR2 antibodies be effectively used to study receptor activation in response to collagen?

To study DDR2 activation in response to collagen:

• Collagen preparation:

  • Use acid-solubilized collagen I (100 μg/ml final concentration)

  • Ensure collagen maintains triple-helical structure (heat-denatured collagen fails to activate DDR2)

  • Consider using different collagen types (I, II, III, X) to study type-specific responses

• Experimental design:

  • Include extended time points (1h, 8h, 24h, 48h) as DDR2 activation is unusually slow

  • Use 3D collagen matrices for physiologically relevant activation

  • Parallel assessment of phosphorylation and downstream signaling (SHP-2 phosphorylation)

• Readouts:

  • Receptor phosphorylation (Western blot with phospho-tyrosine antibodies)

  • Downstream target activation (e.g., SHP-2 phosphorylation at Tyr542)

  • Matrix metalloproteinase expression and activation (e.g., MMP-1, MMP-2)

  • 3D colony formation assays in collagen gels to assess functional outcomes

Research data confirms that DDR2 interacts with collagen through its discoidin domain, and this interaction triggers slow but sustained receptor phosphorylation, leading to downstream signaling through pathways involving SHP-2 phosphorylation .

What approaches are effective for studying DDR2 mutants associated with disease states?

For investigating DDR2 mutations found in diseases like lung squamous cell carcinoma:

• Expression system selection:

  • Transiently transfect DDR2 mutants into DDR2-negative cell lines

  • Generate stable cell lines for long-term studies

  • Consider using physiologically relevant cells that express DDR2 natively

• Functional characterization:

  • Colony formation assays in 3D collagen matrices

  • Receptor autophosphorylation analysis (total and site-specific)

  • Downstream signaling pathway activation (especially SHP-2 phosphorylation)

• Analytical methods:

  • Western blotting with phosphotyrosine antibodies

  • Selected reaction monitoring (SRM) mass spectrometry for quantitative phosphorylation analysis

  • Normalized densitometry measurements of phosphotyrosine signals

Research data shows that certain DDR2 mutations found in lung squamous cell carcinoma exhibit altered phosphorylation patterns and downstream signaling compared to wild-type DDR2. For example, colony formation assays in 3D collagen gels demonstrated differential growth patterns between wild-type and mutant DDR2-expressing cells .

How can DDR2 antibodies be applied to study interactions with matrix metalloproteinases (MMPs)?

To investigate DDR2-MMP interactions:

• Experimental approaches:

  • Collagen film degradation assays with DDR2 knockdown/overexpression

  • Zymography to assess MMP-2 activation states (pro-MMP-2 vs. active MMP-2)

  • Transwell collagen invasion assays with DDR2 manipulation

  • Co-immunoprecipitation of DDR2 with MT1-MMP or other MMPs

• Controls and comparisons:

  • Include β1 integrin knockdown/blocking as a comparison control

  • Use DDR2 kinase inhibitors (e.g., dasatinib) to differentiate between expression and activity effects

  • Compare multiple collagen types (I, II) from different sources

• Validation methods:

  • Western blotting to confirm knockdown efficiency

  • Parallel assessment of DDR2 phosphorylation and MMP activation

  • Immunofluorescence co-localization of DDR2 and MMPs at sites of matrix degradation

Research shows that DDR2 plays a critical role in MT1-MMP-dependent collagen degradation and invasion, independent of integrin function. When DDR2 was knocked down in rheumatoid arthritis synovial fibroblasts (RASF), collagen degradation and invasion capabilities were significantly reduced, while integrin β1 knockdown had less impact .

What criteria should guide selection between monoclonal and polyclonal DDR2 antibodies?

When choosing between monoclonal and polyclonal DDR2 antibodies:

For example, the monoclonal DDR2 Antibody (3B11E4) provides high specificity for detection of DDR2 in mouse, rat, and human samples in Western blot, IP, IF, and IHC applications , while the polyclonal Human DDR2 Antibody from R&D Systems offers broad application versatility with approximately 5% cross-reactivity with DDR1 .

How can researchers effectively distinguish between DDR1 and DDR2 in experimental systems?

Despite sharing 53% amino acid sequence identity in their extracellular domains , researchers can distinguish between DDR1 and DDR2 through:

• Antibody selection:

  • Choose antibodies raised against regions with minimal homology between DDR1 and DDR2

  • Validate antibody specificity using cells known to express only DDR1, only DDR2, or both receptors

  • Western blotting analysis shows that some cell types (like HT1080) express both DDR1 and DDR2, while others (like RASF and HDF) express DDR2 but not DDR1

• Expression analysis:

  • Use RT-qPCR with primer sets specific to non-homologous regions

  • Compare expression patterns across tissues (DDR1 and DDR2 have distinct tissue distribution)

  • Employ siRNA knockdown validation to confirm antibody specificity

• Functional discrimination:

  • DDR1 and DDR2 have distinct collagen type preferences (DDR1 binds collagens I-V, while DDR2 has higher specificity for fibrillar collagens I and III)

  • Utilize selective inhibitors when available

  • Assess downstream signaling pathways (some are unique to each receptor)

In experimental validation, Western blot analyses of HT1080 human fibrosarcoma cells, RASF, and HDF demonstrated that HT1080 cells express both DDR receptors, while RASF and HDF express DDR2 but not DDR1 , providing an experimental system for DDR2-specific studies.

What considerations apply when selecting DDR2 antibodies for different imaging techniques?

For optimal DDR2 visualization across imaging methods:

For immunohistochemistry applications, Mouse Anti-Human DDR2 Monoclonal Antibody has been successfully used at 15 μg/mL with overnight incubation at 4°C, followed by detection using HRP-DAB staining systems .

How can researchers effectively study DDR2-dependent signaling pathways?

To elucidate DDR2 signaling networks:

• Temporal considerations:

  • Unlike most RTKs, DDR2 activation is slow (hours to days), requiring extended time points

  • Research shows distinct temporal profiles for different DDR2 phosphorylation sites following collagen stimulation

  • Design experiments with multiple time points (0, 1, 4, 8, 24, 48, 72h)

• Pathway analysis approaches:

  • Phospho-specific antibody arrays for broad pathway screening

  • Immunoprecipitation followed by mass spectrometry

  • SHP-2 phosphorylation assessment (at Tyr542 and Tyr62) as a key downstream event

  • MMP expression/activation as functional readouts

• Validation strategies:

  • Kinase-dead DDR2 mutants (K608M and K608E) as negative controls

  • Pharmacological inhibitors (e.g., dasatinib)

  • siRNA knockdown of DDR2 and pathway components

  • Rescue experiments with wild-type DDR2 expression

Research data demonstrates that DDR2 activation leads to phosphorylation of SHP-2 at multiple sites, with temporal upregulation occurring after collagen stimulation. This phosphorylation is dependent on DDR2 kinase activity, as kinase-dead mutants (K608M and K608E) failed to induce SHP-2 phosphorylation .

What are the best practices for analyzing DDR2 interactions with the extracellular matrix?

To study DDR2-ECM interactions:

• Matrix preparation considerations:

  • Native triple-helical collagen structure is essential for DDR2 activation

  • Different collagen types (I, II, III, X) can yield distinct responses

  • Consider using both soluble collagen and 3D matrix environments

• Interaction analysis methods:

  • Solid-phase binding assays with purified proteins

  • Surface plasmon resonance (SPR) for binding kinetics

  • Proximity ligation assays (PLA) in tissues

  • Fluorescence resonance energy transfer (FRET) with labeled collagen

• Functional consequences assessment:

  • Collagen fibrillogenesis assays (DDR2 alters collagen fiber morphology)

  • Matrix degradation assays using fluorescent collagen

  • 3D cell culture in collagen matrices

  • Transwell collagen invasion assays

Research indicates that DDR2 selectively recognizes the triple-helical structure of collagen compared to monomeric or denatured collagen, and the discoidin-like domain mediates DDR2 interactions with collagens I, III, and X, while collagens II and V are less efficacious ligands . When studying collagen II interactions specifically, different regions of the collagen molecule (D1 and D2 periods) play distinct roles in binding and triggering DDR2 autophosphorylation .

What emerging applications of DDR2 antibodies should researchers consider?

Emerging research approaches for DDR2 antibodies include:

• Single-cell analysis: Using DDR2 antibodies for single-cell proteomics and flow cytometry to understand cellular heterogeneity in DDR2 expression and activation in cancer and fibrosis.

• Therapeutic targeting: Development of function-blocking DDR2 antibodies as potential therapeutics for fibrotic diseases and cancer, particularly in contexts where DDR2 mutations drive disease progression.

• Multiplexed imaging: Integration of DDR2 antibodies into multiplexed immunofluorescence panels for spatial analysis of DDR2 in relation to other signaling molecules and matrix components in tissue contexts.

• Extracellular vesicle studies: Investigating DDR2 presence on extracellular vesicles as potential biomarkers or mediators of intercellular communication in disease states.

• Nanobody development: Creation of DDR2-specific nanobodies for improved tissue penetration and super-resolution imaging applications.

Research findings indicate that DDR2 plays critical roles in collagenous matrix destruction, cell invasiveness, and is upregulated in several pathological conditions, including hepatic fibrosis, rheumatoid and osteoarthritis, and smooth muscle cell hyperplasia , making it a valuable target for these emerging applications.

How should researchers interpret contradictory findings when using different DDR2 antibodies?

When facing contradictory results with different DDR2 antibodies:

• Epitope mapping considerations:

  • Antibodies recognizing different epitopes may yield distinct results due to:

    • Epitope masking by protein interactions

    • Conformation-dependent epitope accessibility

    • Post-translational modifications affecting epitope recognition

• Validation approaches:

  • Confirm findings with at least two independent antibodies

  • Use genetic approaches (siRNA, CRISPR) as complementary validation

  • Consider species differences if using antibodies across model systems

• Technical variables:

  • Sample preparation methods affecting protein conformation

  • Fixation conditions altering epitope accessibility

  • Buffer conditions affecting antibody binding

• Resolution strategies:

  • Perform side-by-side comparisons under identical conditions

  • Validate with non-antibody-based approaches (e.g., mass spectrometry)

  • Consider isoform or splice variant detection differences